Genmab
Clinical trials sponsored by Genmab, explained in plain language.
-
New Two-Pronged attack tested for Tough-to-Treat skin cancer
Disease control OngoingThis study is testing whether a new drug called acasunlimab works better alone or combined with an existing cancer drug (pembrolizumab) for people with advanced skin melanoma that has continued to grow despite prior immunotherapy. All participants will receive active treatment—no…
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
New hope for elderly lymphoma patients who Can't handle standard chemo
Disease control OngoingThis study is testing a new antibody drug called epcoritamab, both alone and combined with another drug called lenalidomide, for older adults newly diagnosed with an aggressive type of lymphoma. The goal is to find a safer and effective first treatment for patients who are too fr…
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New weapon tested against tough cancers
Disease control OngoingThis early-stage trial is testing a new drug called GEN1047 in people with advanced solid tumors, including breast, ovarian, endometrial, and a type of lung cancer. The main goals are to find a safe dose, understand how the body processes the drug, and see if it can shrink tumors…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug trial offers hope for patients with Tough-to-Treat lymphoma
Disease control OngoingThis clinical trial is testing a new drug called epcoritamab in people with B-cell lymphoma that has come back or hasn't responded to previous treatments. The main goals are to find a safe and effective dose, understand the side effects, and see how well the drug works to control…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New shot offers hope for patients with Tough-to-Treat blood cancer
Disease control OngoingThis study is comparing a new injectable drug called epcoritamab against standard chemotherapy for people with an aggressive type of lymphoma that has come back or stopped responding to previous treatments. About 484 participants will be randomly assigned to receive either the ne…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New drug trial offers hope for japanese lymphoma patients who have run out of options
Disease control OngoingThis study is testing a new drug called epcoritamab in Japanese adults with B-cell lymphoma that has come back or stopped responding to standard treatments. The first part of the study aims to find a safe and effective dose. The second part will test that dose, both alone and com…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New shot offers hope for Tough-to-Treat blood cancer
Disease control OngoingThis trial is testing if a new drug called epcoritamab works better than standard chemotherapy for people with an aggressive type of lymphoma that has come back or stopped responding to prior treatments. Participants will be randomly assigned to receive either the new drug as an …
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo trial offers hope for tough blood cancers
Disease control OngoingThis study is testing a new drug called epcoritamab to see if it is safe and effective for people with certain hard-to-treat blood cancers. It is for adults with chronic lymphocytic leukemia (CLL) or Richter's syndrome that has come back or not responded to other treatments. The …
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New cancer drug begins human testing for Tough-to-Treat tumors
Disease control OngoingThis early-stage trial is testing a new drug called GEN1286 in adults with advanced solid tumors that have spread or returned after other treatments. The main goals are to find a safe dose and see if the drug can help shrink tumors. The study is divided into two parts: first find…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo trial offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis trial is testing the safety and early effectiveness of a new drug called epcoritamab, given alone or combined with standard treatments, for people with B-cell non-Hodgkin lymphoma. It includes over 500 participants with different types and stages of the disease, including ne…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for Tough-to-Treat lung cancer: experimental drug trial
Disease control OngoingThis study is testing an experimental drug called acasunlimab (GEN1046) for people with advanced non-small cell lung cancer that has returned or stopped responding to standard immunotherapy. Researchers want to see if the drug works better when given alone or combined with anothe…
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New antibody drug trial offers hope for Tough-to-Treat cancers
Disease control OngoingThis early-stage trial is testing a new antibody drug called GEN1042 to see if it's safe and can help control advanced solid tumors. Researchers are giving GEN1042 alone or combined with another cancer drug (pembrolizumab) to about 350 adults with cancers like lung, colorectal, m…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for Tough-to-Treat lung cancer: experimental combo enters final testing
Disease control OngoingThis trial is testing whether a new drug called acasunlimab, when combined with pembrolizumab, works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer. It is for patients whose cancer has spread, is PD-L1 positive, and has gotten wo…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for women with aggressive ovarian cancer in global drug trial
Disease control OngoingThis global study is testing whether a new drug called Rina-S works better than current standard chemotherapy for women with platinum-resistant ovarian cancer. All 530 participants will receive active treatment—either Rina-S or one of four approved chemotherapy drugs—with a 50/50…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New cancer drug begins first human tests in japan
Disease control OngoingThis early-stage study is testing a new cancer drug called GEN1042 in Japanese patients with advanced solid tumors. Researchers will first give GEN1042 alone to check safety, then test it combined with other cancer drugs. The main goal is to find safe doses and see how the body h…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New cancer drug shows promise in early human trials
Disease control OngoingThis early-stage trial is testing a new antibody drug called acasunlimab (GEN1046) for people with advanced solid tumors. The study first aims to find safe doses, then tests how well those doses work when given alone or combined with other cancer drugs. All 429 participants will …
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC